As this is a constantly evolving field, regardless of the treatment received, all SMA cases may benefit from knowing their complete SMN2 genotype to make better and tight correlations with each phenotype and more realistic outcomes after therapies. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.